Its values, its interview process and the questions it asks, in short episodes. Listen on a walk, then practice.
10 episodes1 free to try
No subscription needed
Merck isn't just oncology — it has one of the world's largest animal-health businesses, a top-three vaccines franchise, and a manufacturing empire. Most candidates focus only on the human-pharma side. This module covers Merck Animal Health (Rick DeLuca's $5B+ business), the vaccines portfolio, and how candidates demonstrate fit for Merck's full mission.
Merck in 2026 is a company under real pressure — Gardasil sales collapsed 39% in 2025, the company announced 6,000 job cuts and a $3B cost-savings program, the stock has been volatile. This module covers the headwinds candidly and shows candidates how to talk about adversity, layoffs, and resilience in a way that matches how Merck leaders discuss it.
Merck isn't just a 130-year-old pharma — it's a company aggressively investing in AI, digital tools, modern manufacturing, and a reimagined Rahway campus. This module covers Dave Williams' digital strategy, generative AI deployment, the $450M FLEx Center, and how candidates demonstrate the "innovation and scientific excellence" value in practice.
"Why Merck?" is the single most common Merck interview question and the one most candidates fail. This module gives you the materials to build a genuinely specific answer rooted in Merck's history (penicillin, cortisone, Mectizan donation), its current pipeline distinctiveness, and the science culture Dean Li has shaped — so you sound like someone who chose Merck, not pharma generally.
Merck's careers site is unusually explicit: "All of our interviews are behavior-based." This module walks through Merck's official hiring stages, the STAR-method expectation, panel formats, the 36-day process timeline, and the specific behavioral questions candidates report being asked.
On February 23, 2026, Merck announced one of the biggest reorganizations in its history — splitting Human Health into a standalone Oncology unit and a Specialty/Pharma/Infectious Diseases unit. This module explains the structure, the leaders (Jannie Oosthuizen and Brian Foard), and why interviewers will care that you understand it.
Merck's official four values aren't a poster on the wall — they show up in actual decisions, including the moment Ken Frazier resigned from a presidential council on principle. This module decodes each value, ties it to a real Merck moment, and gives candidates a STAR-ready story for each.
"One Pipeline" is the operating philosophy of Merck Research Laboratories — the idea that the best science wins, whether it comes from inside Merck's labs or from a partner. This module covers Dean Li's strategy, the BD&L hubs in Boston/Cambridge/London/Shanghai, and the specific deals (Verona, Cidara, Acceleron) that shape how Merck talks about collaboration in interviews.
Every Merck candidate in 2026 should walk into the room knowing exactly what "the Keytruda cliff" means and what the company is doing about it. This module covers the 2028 patent loss, the $35B peak, the QLEX subcutaneous formulation, and CEO Rob Davis's $70B revenue ambition for the mid-2030s — strategic context that lets you answer "where do you see yourself fitting in?" with real substance.
Almost every behavioral interview at Merck eventually circles back to one quote from 1950. This module unpacks George W. Merck's "medicine is for the patient" speech, why it ended up on the cover of Time magazine, and exactly how it translates into interview questions you'll be asked today — including how to weave a "patient-first" mindset into your STAR stories without sounding canned.